Cell therapy in patients with COVID-19 using Wharton’s jelly mesenchymal stem cells: a phase 1 clinical trial

BACKGROUND: Mesenchymal stem cells (MSCs) have received particular attention because of their ability to modulate the immune system and inhibit inflammation caused by cytokine storms due to SARS-CoV-2. New alternative therapies may reduce mortality rates in patients with COVID19. This study aimed to...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Stem Cell Res Ther
Main Authors: Saleh, Mahshid, Vaezi, Amir Abbas, Aliannejad, Rasoul, Sohrabpour, Amir Ali, Kiaei, Seyedeh Zahra Fotook, Shadnoush, Mahdi, Siavashi, Vahid, Aghaghazvini, Leila, Khoundabi, Batoul, Abdoli, Shahriyar, Chahardouli, Bahram, Seyhoun, Iman, Alijani, Neda, Verdi, Javad
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2021
Teme:
Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC8283394/
https://ncbi.nlm.nih.gov/pubmed/34271988
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13287-021-02483-7
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki